Novartis to Seek FDA Emergency Use Approval for New COVID-19 Therapy

Published on January 10, 2022

Novartis said the drug's so-called multi-specific protein-based domains ensure strong neutralization of the CCP virus, even in the face of mutations of the pathogen's spike protein, while limiting the development of escape mutants.

Continue reading on website
Other news

Sticky Inflation and Job Market Tightening Will Push Fed to Hike Rates 4 Times in 2022: Goldman Sachs

January 10, 2022
Jan Hatzius, chief economist at Goldman, wrote in a note Sunday that the investment bank is predicting a fourth 25-basis-point rate hike in December of this year, up from an earlier projection of three.

Learn to Scale Your Business with These 10 Books

January 10, 2022
Before going big, check out the recommendations, lessons learned and innovative concepts.